LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

This study tests LM-108 (an experimental targeted antibody) combined with sintilimab (an immunotherapy drug) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) — the most common type of lung cancer. **You may be eligible if...** - You are 18 or older - You have confirmed locally advanced (stage IIIB/IIIC) or metastatic (stage IV) NSCLC that cannot be surgically removed or cured with radiation - Your cancer does not have EGFR, ALK, ROS1, or other targetable mutations (or mutations without approved targeted treatments) - Your performance status and organ function are adequate **You may NOT be eligible if...** - You have an EGFR mutation or other actionable mutation with an approved targeted therapy - You have small cell lung cancer - You have active autoimmune disease - You have active brain metastases requiring steroids Talk to your doctor to see if this trial is right for you.